Merck LIPFENDRA (Enlicitide) US Retail Launch Details Confirm $10.50 Per Tablet List Price ($315 Per 30-Day Supply Before Insurance and Manufacturer Support), Distribution Through Standard Retail and Mail-Order Pharmacies Under the Pharmacy Benefit (Unlike Novartis Leqvio Which Runs Through the Medical Benefit), and Expected Pharmacy Availability Within Weeks Following the Thursday July 16 FDA Approval as the First and Only Once-Daily Oral PCSK9 Inhibitor
Merck LIPFENDRA (enlicitide) commercial-launch details firmed up in the days following Thursday July 16, 2026 FDA approval. List price: $10.50 per tablet, or $315 per 30-day supply before insurance discounts, manufacturer support, or pharmacy benefit adjustments. Distribution channel: standard retail and mail-order pharmacies under the pharmacy benefit, which contrasts with Novartis Leqvio (inclisiran) that runs through the medical benefit due to healthcare-provider subcutaneous administration. Expected pharmacy availability: within weeks of approval. The pharmacy benefit pathway matters for real-world access because it eliminates the buy-and-bill logistics that have slowed injectable PCSK9 adoption (Repatha, Praluent, Leqvio) and puts LIPFENDRA on the same pharmacy shelf as statins and cheaper oral non-statin drugs like Nexletol (bempedoic acid) and Zetia (ezetimibe). The macrocyclic peptide's ability to survive gastrointestinal enzymes is what allows the oral delivery model that unlocks the pharmacy-benefit distribution advantage.